Increasing worldwide ear infection prevalence and high need for safe and effective ear infection treatment are projected to drive the global ear infection treatment market during the forecast period. Pfizer purchased Amplyx Pharmaceuticals in the United States in April 2021 to develop its infectious disease expertise and boost its anti-infectives pipeline. The high cost of treatment is projected to stymie the expansion of the worldwide ear infection treatment market. Problems from medical operations are likely to stifle the spread of the pandemic ear infection. Cigarette smoke exposure, as well as continuous innovation and increased knowledge of ear infections, are predicted to grow. Increased R&D spending and the introduction of innovative products by industry players are projected to fuel the growth of the worldwide ear infection treatment market.
According to Coherent Market Insights, the global Ear Infection Treatment Market was valued at US$ 10,671.9 Mn in 2021 and is forecast to reach a value of US$ 14,345.6 Mn by 2028 at a CAGR of 4.3% between 2022 and 2028.
Key Manufacturers in the Ear Infection Treatment Industry:
1. Olympus Corporation
Olympus Corp manufactures and sells precision instruments for the healthcare industry. The firm operates in three segments: scientific solutions, imaging, and medical. The scientific solutions segment sells microscopes and other imaging tools to life sciences and industrial customers. The imaging segment sells digital cameras under the Olympus brand. The company was founded in 1919, headquartered in Tokyo, Japan.
2. American Diagnostic Corporation
Manufacturer of diagnostic medical devices catering to the healthcare industry. The company manufactures diagnostic medical products, patient monitoring systems, blood pressure instruments, pulse oximeters, stethoscopes and other related products for its clients. The company was founded in 1984, headquartered in U.S.
3. Pfizer Plc
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. In April 2021, Pfizer acquired US-based Amplyx Pharmaceuticals to advance its expertise in infectious disease and expand its anti-infectives pipeline.
4. Novartis AG
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.
5. Grace Medical
The company was founded in 2018, headquartered in 2018. In September 2019, Grace Medical, a leader in ear nose and throat surgical devices with a focus on otology, announced it has acquired EndoEar Endoscopic Instruments to access and remove hard-to-reach disease in the middle ear. This acquisition solidifies Grace Medical’s position as the global leader in ENT technology and innovation.
6. Sanofi SA
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions and was founded in 1973. The company is headquartered in Paris, France. In November 2021, Sanofi acquired Kadmon Holdings Inc. The acquisition further strengthens growth and expansion for the General Medicines portfolio.
7.GlaxoSmithKline
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. In May 2020, GlaxoSmithKline clinical study showed that Synflorix, a pneumococcal vaccine, can effectively prevent Korea-Acute Otitis Media (K-AOM) among Korean infants.
8. Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. On November 2019, FDA approves J&J spinout’s device for kids with recurring ear infections
9. Cipla Ltd.
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
*Definition- When bacteria or viruses infect and trap fluid behind the eardrum, it causes discomfort and swelling/bulging of the eardrum.
